Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (CORT) announced it will report its third quarter financial results on November 3, 2020. A corporate update will accompany the earnings report, alongside a conference call at 5:00 p.m. ET. To participate, attendees can register via a link or dial in using specified phone numbers. The replay of the call will be accessible until November 17, 2020. Corcept is focused on developing drugs for severe disorders by modulating cortisol's effects, with its approved drug Korlym® targeting Cushing’s syndrome, supported by a robust intellectual property portfolio.
Corcept Therapeutics (NASDAQ: CORT) has commenced the GRATITUDE II trial to assess miricorilant in obese patients with schizophrenia suffering from antipsychotic-induced weight gain. The study aims to enroll 150 participants, who will receive either miricorilant or placebo alongside their antipsychotic medication for 26 weeks. This follows the promising results of the Phase 1b trial, which indicated that miricorilant could reduce weight gain and liver enzyme levels in patients. This trial utilizes an enhanced formulation of miricorilant to build on previous findings.
Corcept Therapeutics reported strong financial results for Q2 2020, with revenue at $88.6 million, a 23% increase from Q2 2019. GAAP diluted net income rose to $0.23 per share from $0.17 YoY, while non-GAAP diluted net income also improved to $0.32 per share from $0.25. Cash and investments increased to $409.6 million. The company reaffirmed its 2020 revenue guidance at $355 million to $375 million, despite a slight revenue decrease compared to Q1 due to patient prescription shifts amid the COVID-19 pandemic.
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and corporate update on August 4, 2020. A conference call will follow at 5:00 p.m. ET where participants can join by calling 1-800-353-6461 in the U.S. or 1-334-323-0501 internationally.
Corcept focuses on developing drugs that target cortisol effects for severe metabolic, oncologic, and psychiatric disorders. Its first product, Korlym®, is approved for Cushing’s syndrome. The company holds significant intellectual property related to its cortisol modulators.
Corcept Therapeutics (NASDAQ: CORT) has enrolled its first patient in the GRADIENT Phase 3 trial of relacorilant for Cushing's syndrome due to adrenal adenomas or hyperplasia. This double-blind, placebo-controlled study aims to include 130 patients in the U.S. and Europe, assessing glucose metabolism and hypertension over six months. Relacorilant, an innovative glucocorticoid receptor modulator, has already shown promise in the ongoing GRACE trial for various Cushing's syndrome causes. These initiatives could strengthen treatment options and drive market growth.
Corcept Therapeutics (NASDAQ: CORT) has completed patient enrollment in its Phase 2 trial of relacorilant combined with nab-paclitaxel for treating metastatic, platinum-resistant ovarian cancer. A total of 177 patients were enrolled across 28 sites in North America and Europe. The primary endpoint focuses on progression-free survival, alongside secondary measures like objective response rates. Following promising Phase 1/2 results, data from this trial are expected in the first half of the next year, positioning Corcept for potential advancements in its clinical portfolio.
Corcept Therapeutics (NASDAQ: CORT) has commenced the RELIANT trial, an open-label, Phase 3 study evaluating relacorilant in combination with nab-paclitaxel for treating metastatic pancreatic cancer. The trial aims to enroll 80 patients, with the primary endpoint being objective response rate. Interim data will be analyzed after the first 40 patients are enrolled. This follows encouraging results from a Phase 1/2 study presented at ASCO last year, indicating potential for accelerated approval if results are positive.
Corcept Therapeutics (NASDAQ: CORT) will present new genomic data on adrenocortical carcinoma at the 2020 AACR Annual Meeting, starting June 22. The data, which addresses excessive cortisol, is critical for their Phase 1b trial of relacorilant with pembrolizumab in patients with advanced cancer. This research aims to enhance immunotherapy's efficacy by mitigating cortisol's negative effects. The poster presentation is set for a virtual format and will be available online following the meeting.
Corcept Therapeutics reported Q1 2020 financial results with revenue of $93.2 million, up 44% year-over-year. GAAP net income rose to $30.1 million, with diluted EPS of $0.25. Non-GAAP diluted EPS was $0.34, compared to $0.20 in Q1 2019. Cash and investments increased to $349.0 million. The company maintained its 2020 revenue guidance of $355-375 million. However, COVID-19 has impacted clinical trial enrollments and timelines, but the firm anticipates ongoing developments and results from ongoing trials this year.
Summary not available.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
